Craig A Harrison

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7688316/publications.pdf

Version: 2024-02-01

52 papers	2,351 citations	201674 27 h-index	214800 47 g-index
52 all docs	52 docs citations	52 times ranked	3320 citing authors

#	Article	IF	Citations
1	Targeting TGF-Î² Mediated SMAD Signaling for the Prevention of Fibrosis. Frontiers in Pharmacology, 2017, 8, 461.	3.5	393
2	Antagonists of activin signaling: mechanisms and potential biological applications. Trends in Endocrinology and Metabolism, 2005, 16, 73-78.	7.1	188
3	Cumulin, an Oocyte-secreted Heterodimer of the Transforming Growth Factor-Î² Family, Is a Potent Activator of Granulosa Cells and Improves Oocyte Quality. Journal of Biological Chemistry, 2015, 290, 24007-24020.	3.4	130
4	Prodomains regulate the synthesis, extracellular localisation and activity of TGF-Î² superfamily ligands. Growth Factors, 2011, 29, 174-186.	1.7	99
5	Structural basis for potency differences between GDF8 and GDF11. BMC Biology, 2017, 15, 19.	3.8	90
6	Specific targeting of TGF-Î² family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5266-E5275.	7.1	90
7	New insights into the mechanisms of activin action and inhibition. Molecular and Cellular Endocrinology, 2012, 359, 2-12.	3.2	81
8	Activins and Inhibins and Their Signaling. Annals of the New York Academy of Sciences, 2004, 1038, 142-147.	3.8	71
9	Identification of Distinct Inhibin and Transforming Growth Factor Î²-binding Sites on Betaglycan. Journal of Biological Chemistry, 2006, 281, 17011-17022.	3.4	71
10	Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. Science Translational Medicine, 2016, 8, 348ra98.	12.4	70
11	The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget, 2017, 8, 18640-18656.	1.8	66
12	An Activin Mutant with Disrupted ALK4 Binding Blocks Signaling via Type II Receptors. Journal of Biological Chemistry, 2004, 279, 28036-28044.	3.4	63
13	A Common Biosynthetic Pathway Governs the Dimerization and Secretion of Inhibin and Related Transforming Growth Factor Î² (TGFÎ²) Ligands. Journal of Biological Chemistry, 2009, 284, 9311-9320.	3.4	63
14	Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia. Cancer Research, 2016, 76, 5372-5382.	0.9	62
15	The TGF-Î² Signalling Network in Muscle Development, Adaptation and Disease. Advances in Experimental Medicine and Biology, 2016, 900, 97-131.	1.6	56
16	Identification of a Functional Binding Site for Activin on the Type I Receptor ALK4. Journal of Biological Chemistry, 2003, 278, 21129-21135.	3.4	49
17	Inhibin A and B in Vitro Bioactivities Are Modified by Their Degree of Glycosylation and Their Affinities to Betaglycan. Endocrinology, 2007, 148, 2309-2316.	2.8	47
18	Development of Novel Activin-Targeted Therapeutics. Molecular Therapy, 2015, 23, 434-444.	8.2	46

#	Article	IF	Citations
19	Suppression of Inhibin A Biological Activity by Alterations in the Binding Site for Betaglycan. Journal of Biological Chemistry, 2008, 283, 16743-16751.	3.4	42
20	Activation of Latent Human GDF9 by a Single Residue Change (Gly391Arg) in the Mature Domain. Endocrinology, 2012, 153, 1301-1310.	2.8	40
21	Inhibin B Is a More Potent Suppressor of Rat Follicle-Stimulating Hormone Release than Inhibin A in Vitro and in Vivo. Endocrinology, 2009, 150, 4784-4793.	2.8	38
22	Identification of Specific Inhibin A-Binding Proteins on Mouse Leydig (TM3) and Sertoli (TM4) Cell Lines*. Endocrinology, 2001, 142, 1393-1402.	2.8	36
23	Inhibin binding sites and proteins in pituitary, gonadal, adrenal and bone cells. Molecular and Cellular Endocrinology, 2001, 180, 63-71.	3.2	34
24	Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Science Translational Medicine, 2018, 10, .	12.4	32
25	BMP15 Mutations Associated With Primary Ovarian Insufficiency Reduce Expression, Activity, or Synergy With GDF9. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1009-1019.	3.6	31
26	Molecular characterization of latent GDF8 reveals mechanisms of activation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E866-E875.	7.1	30
27	Aberrant GDF9 Expression and Activation Are Associated With Common Human Ovarian Disorders. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E615-E624.	3.6	29
28	Species Differences in the Expression and Activity of Bone Morphogenetic Protein 15. Endocrinology, 2013, 154, 888-899.	2.8	28
29	A variant of human growth differentiation factor-9 that improves oocyte developmental competence. Journal of Biological Chemistry, 2020, 295, 7981-7991.	3.4	28
30	Structure of AMH bound to AMHR2 provides insight into a unique signaling pair in the TGF-Î² family. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	26
31	Activin-A Binds Follistatin and Type II Receptors through Overlapping Binding Sites: Generation of Mutants with Isolated Binding Activities. Endocrinology, 2006, 147, 2744-2753.	2.8	25
32	TGFBR3L is an inhibin B co-receptor that regulates female fertility. Science Advances, 2021, 7, eabl4391.	10.3	21
33	Serum Concentrations of Oocyte-Secreted Factors BMP15 and GDF9 During IVF and in Women With Reproductive Pathologies. Endocrinology, 2019, 160, 2298-2313.	2.8	19
34	Activin Aâ€“Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice. Endocrinology, 2019, 160, 2417-2426.	2.8	17
35	Cumulin and FSH Cooperate to Regulate Inhibin B and Activin B Production by Human Granulosa-Lutein Cells In Vitro. Endocrinology, 2019, 160, 853-862.	2.8	17
36	Extra-ovarian expression and activity of growth differentiation factor 9. Journal of Endocrinology, 2009, 202, 419-430.	2.6	16

#	Article	IF	Citations
37	Biological activity and inÂvivo half-life of pro-activin A in male rats. Molecular and Cellular Endocrinology, 2016, 422, 84-92.	3.2	14
38	Multiple Soluble TGF-Î² Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF-Î² Signaling. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3065-3074.	3.6	13
39	Inhibin Biosynthesis and Activity Are Limited by a Prodomain-Derived Peptide. Endocrinology, 2015, 156, 3047-3057.	2.8	10
40	A Novel, More Efficient Approach to Generate Bioactive Inhibins. Endocrinology, 2016, 157, 2799-2809.	2.8	10
41	Potential treatment of keloid pathogenesis with follistatin 288 by blocking the activin molecular pathway. Experimental Dermatology, 2021, 30, 402-408.	2.9	9
42	Engineering the Ovarian Hormones Inhibin A and Inhibin B to Enhance Synthesis and Activity. Endocrinology, 2020, 161, .	2.8	8
43	Effect of cumulin and super-GDF9 in standard and biphasic mouse IVM. Journal of Assisted Reproduction and Genetics, 2022, 39, 127-140.	2.5	8
44	Use of detergent-based buffers allows detection of precursor inhibin forms in an immunoassay format. Molecular and Cellular Endocrinology, 2013, 381, 106-114.	3.2	6
45	Readiness to Change and Reasons for Intended Reduction of Alcohol Consumption in Emergency Department versus Trauma Population. Western Journal of Emergency Medicine, 2014, 15, 337-344.	1.1	6
46	TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass. Frontiers in Physiology, 2020, 11, 560225.	2.8	5
47	Interleukin 11 and Activin A Synergise to Enhance Medroxyprogesterone But Not cAMP-Induced Decidualization of Human Endometrial Stromal Cells.. Biology of Reproduction, 2008, 78, 143-143.	2.7	5
48	Inhibin Inactivation in Female Mice Leads to Elevated FSH Levels, Ovarian Overstimulation, and Pregnancy Loss. Endocrinology, 2022, 163, .	2.8	5
49	Selection of internal control genes for analysis of gene expression in normal and diseased human dermal fibroblasts using quantitative realâ€time <scp>PCR</scp>. Experimental Dermatology, 2016, 25, 911-914.	2.9	3
50	Functional Characterization of Two New Variants in the Bone Morphogenetic Protein 7 Prodomain in Two Pairs of Monozygotic Twins With Hypospadias. Journal of the Endocrine Society, 2019, 3, 814-824.	0.2	2
51	Human INHBB Gene Variant (c.1079T>C:p.Met360Thr) Alters Testis Germ Cell Content, but Does Not Impact Fertility in Mice. Endocrinology, 2022, 163, .	2.8	2
52	Inhibin: To Betaglycan, or Not to Betaglycan. Endocrinology, 2019, 160, 341-342.	2.8	1